Through September 2024, biopharma firms secured $720.56 million in nonprofit deals, up in value through July and also marking ...

The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...

The drug and device industries have a lot hinging on the results of the Nov. 5 U.S. presidential and congressional elections.

The first filing from Cancerrisk AI Inc. describes their development of a system that uses deep learning to predict future cancer risk from a biopsy image.

Shares of Essa Pharma Inc. tanked Nov. 1 after the company said it is terminating all trials of masofaniten, its N-terminal domain androgen receptor inhibitor and sole clinical-stage program, ...

Previous studies have shown that NETosis, a specialized form of neutrophil-specific cell death, is involved in the ...

Collagen-producing activated myofibroblasts, which are key effector cells in fibrogenesis in different organs, express high ...

For Inocras Inc., the benefits of whole genome sequencing are two-fold. First is its explicit usefulness in diagnosing and treating hard-to-treat diseases like cancer and rare diseases. The second, ...

The ACURATE study of the Accurate neo2 TAVR device by Boston Scientific Corp., failed to demonstrate the device is ...

Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is ...

Researchers from Mariana Oncology Inc. reported preclinical data on MC-339, a DLL3-targeting macrocyclic peptide in several ...

Two recent trials in cardiovascular disease took critical steps toward addressing ongoing and deadly disparities in cardiac care by focusing entirely on women.